Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (NYSE Euronext: MKEA), the leader in the endomicroscopy market, today announced that 50 peer-reviewed scientific articles published on Cellvizio® during 2011 underscore the value of adding cellular-level imaging to endoscopy procedures. The publications, which include 35 on clinical applications, show the strong interest towards endomicroscopic imaging with Cellvizio.
These publications underscore the enormous progress of the medical community in the understanding of endomicroscopy applications for better diagnosis and more appropriate individualized patient care - in gastroenterology and pulmonology, as well as newer investigational applications such as urology. .
"Thanks to this small, flexible microscope, we can reach places that were previously difficult to access," explained Vani Konda, MD, a gastroenterologist at the University of Chicago Medical Center who has used Cellvizio since 2008. "We now benefit from a large body of clinical research work performed in the gastrointestinal field with Cellvizio. It helps us understand how endomicroscopy with probe-based techniques can improve our real-time assessment of regions of interest and pathologies during the endoscopy examination. With this advanced imaging technology, we are able to provide our patients with more accurate diagnoses and faster, more appropriate treatments."
The complete listing of published clinical studies with Cellvizio® is available on Mauna Kea Technologies' web site: http://www.maunakeatech.com/healthcare-professionals/445/bibliography
About Mauna Kea Technologies
Mauna Kea Technologies is a
global medical device company and a leader in endomicroscopic
innovation. The company designs, develops and markets innovative tools
to visualize and help detect abnormalities in the gastrointestinal and
pulmonary tracts. Its flagship product (Cellvizio®, a probe-based
confocal laser endomicroscopy (pCLE) system) provides physicians and
researchers with high-resolution cellular views of tissue inside the
body. Large, international, multicenter clinical trials have
demonstrated Cellvizio®'s ability to help physicians more accurately
detect early forms of disease and make treatment decisions immediately.
Designed to improve patient outcomes and reduce hospital costs,
Cellvizio can be used with almost any endoscope. Cellvizio® has 510(k)
clearance from the U.S. Food and Drug Administration and the European
CE-Mark for use in the gastrointestinal and pulmonary tracts.
For
more information on Mauna Kea Technologies, visit www.maunakeatech.com
Next press release: 2012 financial agenda - January 5, 2012
United States
Erich Sandoval
Lazar
Partners Ltd.
Tel: +1 917 497 2867
esandoval@lazarpartners.com
or
Mauna
Kea Technologies
Alexander Bryson
Marketing
Communications and Brand Manager
Tel: +33 (0) 1 70 08 09 92
alexander@maunakeatech.com
or
France
and Europe
ALIZE RP
Caroline Carmagnol
Tel:
+ 33 1 42 68 86 43 / + 33 6 64 18 99 59
caroline@alizerp.com
Anne?Sophie
Cosquéric
Tel: + 33 1 42 68 86 41 / Anne-sophie@alizerp.com
or
NewCap
Investor
Relations and Financial Communication
Pierre Laurent / Florent Alba
Tel:
+33 1 44 71 94 94 / maunakea@newcap.fr